心脏淀粉样变性:猝死
Cardiac Amyloidosis: Sudden Cardiac Death
摘要: 轻链型心脏淀粉样变性(AL-CA)是心脏淀粉样变性中最具侵袭性的类型,其特点是疾病进展迅速,心源性猝死率异常高。其病理生理机制涉及双重途径:淀粉样纤维对心肌的机械性浸润,以及循环游离轻链对心肌细胞的直接细胞毒性作用。希氏束–浦肯野传导系统的优先受累,使患者易发生致命性心律失常和传导异常。尽管血液系统治疗取得了进展(包括基于达雷妥尤单抗的方案显著提高了缓解率),但即使采取预防性器械干预,猝死仍是患者的主要死亡原因。非特异性的临床表现导致诊断延迟,大多数患者就诊时已处于疾病晚期,且已发生不可逆的心脏损伤。通过系统性多器官评估、心脏生物标志物检测及先进影像学技术实现早期识别,对改善预后至关重要。目前的预防策略包括快速实现血液学缓解、合理使用心脏器械以及精细化血流动力学管理。然而,干预的最佳时机和患者选择标准仍未完全明确。本综述总结了目前对AL-CA猝死机制的认知,评估了循证预防策略,强调迫切需要建立早期诊断流程和个体化治疗方案,以降低心源性猝死对此类患者的严重影响。
Abstract: Light-chain cardiac amyloidosis (AL-CA) represents the most aggressive form of cardiac amyloidosis, characterized by rapid disease progression and exceptionally high sudden cardiac death rates. The pathophysiology involves dual mechanisms: mechanical myocardial infiltration by amyloid fibrils and direct cytotoxic effects of circulating free light chains on cardiomyocytes. Preferential involvement of the His-Purkinje conduction system predisposes patients to fatal arrhythmias and conduction abnormalities. Despite advances in hematologic therapies, including daratumumab-based regimens achieving improved remission rates, sudden death remains the predominant cause of mortality even with prophylactic device interventions. The non-specific clinical presentation results in delayed diagnosis, with most patients presenting at advanced stages when irreversible cardiac damage has occurred. Early recognition through systematic multi-organ assessment, cardiac biomarkers, and advanced imaging techniques is crucial for improving outcomes. Current prevention strategies encompass rapid achievement of hematologic remission, judicious use of cardiac devices, and meticulous hemodynamic management. However, the optimal timing of interventions and patient selection criteria remain incompletely defined. This review synthesizes current understanding of sudden death mechanisms in AL-CA and evaluates evidence-based prevention strategies, highlighting the urgent need for early diagnostic algorithms and individualized treatment approaches to reduce the devastating impact of sudden cardiac death in this population.
文章引用:曹奕玥, 曾瀚庆. 心脏淀粉样变性:猝死[J]. 临床医学进展, 2025, 15(12): 1716-1723. https://doi.org/10.12677/acm.2025.15123585

参考文献

[1] Falk, R.H., Alexander, K.M., Liao, R. and Dorbala, S. (2016) AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology, 68, 1323-1341. [Google Scholar] [CrossRef] [PubMed]
[2] Gertz, M.A., Dispenzieri, A. and Sher, T. (2015) Pathophysiology and Treatment of Cardiac Amyloidosis. Nature Reviews Cardiology, 12, 91-102. [Google Scholar] [CrossRef] [PubMed]
[3] Perfetto, F., Cappelli, F., Bergesio, F., Ciuti, G., Porciani, M.C., Padeletti, L., et al. (2011) Cardiac Amyloidosis: The Heart of the Matter. Internal and Emergency Medicine, 8, 191-203. [Google Scholar] [CrossRef] [PubMed]
[4] Fontana, M., Ćorović, A., Scully, P. and Moon, J.C. (2019) Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC: Cardiovascular Imaging, 12, 2345-2356. [Google Scholar] [CrossRef] [PubMed]
[5] Garcia-Pavia, P., Rapezzi, C., Adler, Y., Arad, M., Basso, C., Brucato, A., et al. (2021) Diagnosis and Treatment of Cardiac Amyloidosis: A Position Statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 42, 1554-1568. [Google Scholar] [CrossRef] [PubMed]
[6] de Frutos, F., Saturi, G., Gonzalez-Lopez, E., Sguazzotti, M., Dominguez, F., Ponziani, A., et al. (2024) Incidence and Predictors of Sudden Death in Patients with Cardiac Amyloidosis. Amyloid, 31, 334-338. [Google Scholar] [CrossRef] [PubMed]
[7] Kharoubi, M., Bodez, D., Bézard, M., Zaroui, A., Galat, A., Guendouz, S., et al. (2022) Describing Mode of Death in Three Major Cardiac Amyloidosis Subtypes to Improve Management and Survival. Amyloid, 29, 79-91. [Google Scholar] [CrossRef] [PubMed]
[8] Chen, Z., Shi, A., Dong, H., Laptseva, N., Chen, F., Yang, J., et al. (2024) Prognostic Implications of Premature Ventricular Contractions and Non-Sustained Ventricular Tachycardia in Light-Chain Cardiac Amyloidosis. Europace, 26, euae063. [Google Scholar] [CrossRef] [PubMed]
[9] Brenner, D.A., Jain, M., Pimentel, D.R., Wang, B., Connors, L.H., Skinner, M., et al. (2004) Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function through an Increase in Cellular Oxidant Stress. Circulation Research, 94, 1008-1010. [Google Scholar] [CrossRef] [PubMed]
[10] Liao, R., Jain, M., Teller, P., Connors, L.H., Ngoy, S., Skinner, M., et al. (2001) Infusion of Light Chains from Patients with Cardiac Amyloidosis Causes Diastolic Dysfunction in Isolated Mouse Hearts. Circulation, 104, 1594-1597. [Google Scholar] [CrossRef] [PubMed]
[11] Shi, J., Guan, J., Jiang, B., Brenner, D.A., del Monte, F., Ward, J.E., et al. (2010) Amyloidogenic Light Chains Induce Cardiomyocyte Contractile Dysfunction and Apoptosis via a Non-Canonical P38α MAPK Pathway. Proceedings of the National Academy of Sciences, 107, 4188-4193. [Google Scholar] [CrossRef] [PubMed]
[12] Siddiqi, O.K. and Ruberg, F.L. (2018) Cardiac Amyloidosis: An Update on Pathophysiology, Diagnosis, and Treatment. Trends in Cardiovascular Medicine, 28, 10-21. [Google Scholar] [CrossRef] [PubMed]
[13] Reisinger, J., Dubrey, S.W., Lavalley, M., Skinner, M. and Falk, R.H. (1997) Electrophysiologic Abnormalities in AL (Primary) Amyloidosis with Cardiac Involvement. Journal of the American College of Cardiology, 30, 1046-1051. [Google Scholar] [CrossRef] [PubMed]
[14] Barbhaiya, C.R., Kumar, S., Baldinger, S.H., Michaud, G.F., Stevenson, W.G., Falk, R., et al. (2016) Electrophysiologic Assessment of Conduction Abnormalities and Atrial Arrhythmias Associated with Amyloid Cardiomyopathy. Heart Rhythm, 13, 383-390. [Google Scholar] [CrossRef] [PubMed]
[15] Hua, D., Yang, Q., Li, X., Zhou, X., Kang, Y., Zhao, Y., et al. (2025) The Combination of Clostridium butyricum and Akkermansia muciniphila Mitigates DSS-Induced Colitis and Attenuates Colitis-Associated Tumorigenesis by Modulating Gut Microbiota and Reducing CD8+ T Cells in Mice. mSystems, 10, e0156724. [Google Scholar] [CrossRef] [PubMed]
[16] Wechalekar, A.D., Fontana, M., Quarta, C.C. and Liedtke, M. (2022) AL Amyloidosis for Cardiologists. JACC: CardioOncology, 4, 427-441. [Google Scholar] [CrossRef] [PubMed]
[17] D’Errico, S., Mazzanti, A., Baldari, B., Maiese, A., Frati, P. and Fineschi, V. (2020) Sudden Death in Lambda Light Chain AL Cardiac Amyloidosis: A Review of Literature and Update for Clinicians and Pathologists. International Journal of Clinical and Experimental Pathology, 13, 1474-1482.
[18] Orini, M., Graham, A.J., Martinez‐Naharro, A., Andrews, C.M., de Marvao, A., Statton, B., et al. (2019) Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. Journal of the American Heart Association, 8, e012097. [Google Scholar] [CrossRef] [PubMed]
[19] Reyners, A., Hazenberg, B.P.C., Reitsma, W.D. and Smit, A.J. (2002) Heart Rate Variability as a Predictor of Mortality in Patients with AA and AL Amyloidosis. European Heart Journal, 23, 157-161. [Google Scholar] [CrossRef] [PubMed]
[20] Wang, Y., Feng, X., Shen, B., Ma, J. and Zhao, W. (2017) Is Vascular Amyloidosis Intertwined with Arterial Aging, Hypertension and Atherosclerosis? Frontiers in Genetics, 8, Article ID: 126. [Google Scholar] [CrossRef] [PubMed]
[21] Ogano, M., Takano, H., Fukuma, N., Takayama, M., Takano, T., Miyagi, Y., et al. (2005) Sudden Death in a Case of Cardiac Amyloidosis Immediately after Pacemaker Implantation for Complete Atrioventricular Block. Journal of Nippon Medical School, 72, 285-289. [Google Scholar] [CrossRef] [PubMed]
[22] Dorbala, S., Vangala, D., Bruyere, J., Quarta, C., Kruger, J., Padera, R., et al. (2014) Coronary Microvascular Dysfunction Is Related to Abnormalities in Myocardial Structure and Function in Cardiac Amyloidosis. JACC: Heart Failure, 2, 358-367. [Google Scholar] [CrossRef] [PubMed]
[23] Aimo, A., Camerini, L., Fabiani, I., Morfino, P., Panichella, G., Barison, A., et al. (2023) Valvular Heart Disease in Patients with Cardiac Amyloidosis. Heart Failure Reviews, 29, 65-77. [Google Scholar] [CrossRef] [PubMed]
[24] Saldanha, M., Chen, L.K., Solomon, J., Cunanan, K., Tournoux, F., Massie, R., et al. (2025) Beyond the Heart: Exploring Extracardiac Manifestations in Cardiac Amyloidosis for Early Diagnosis. Current Cardiology Reports, 27, Article No. 105. [Google Scholar] [CrossRef] [PubMed]
[25] Gertz, M.A. and Dispenzieri, A. (2020) Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA, 324, 79-89. [Google Scholar] [CrossRef] [PubMed]
[26] Kharoubi, M., Bézard, M., Galat, A., Le Bras, F., Poullot, E., Molinier‐Frenkel, V., et al. (2021) History of Extracardiac/Cardiac Events in Cardiac Amyloidosis: Prevalence and Time from Initial Onset to Diagnosis. ESC Heart Failure, 8, 5501-5512. [Google Scholar] [CrossRef] [PubMed]
[27] Cyrille, N.B., Goldsmith, J., Alvarez, J. and Maurer, M.S. (2014) Prevalence and Prognostic Significance of Low QRS Voltage among the Three Main Types of Cardiac Amyloidosis. The American Journal of Cardiology, 114, 1089-1093. [Google Scholar] [CrossRef] [PubMed]
[28] Rahman, J.E., Helou, E.F., Gelzer-Bell, R., Thompson, R.E., Kuo, C., Rodriguez, E.R., et al. (2004) Noninvasive Diagnosis of Biopsy-Proven Cardiac Amyloidosis. Journal of the American College of Cardiology, 43, 410-415. [Google Scholar] [CrossRef] [PubMed]
[29] Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., et al. (2004) Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. Journal of Clinical Oncology, 22, 3751-3757. [Google Scholar] [CrossRef] [PubMed]
[30] Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Colby, C., et al. (2012) Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 30, 989-995. [Google Scholar] [CrossRef] [PubMed]
[31] Palladini, G., Dispenzieri, A., Gertz, M.A., Kumar, S., Wechalekar, A., Hawkins, P.N., et al. (2012) New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 30, 4541-4549. [Google Scholar] [CrossRef] [PubMed]
[32] Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., et al. (2019) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging. Journal of Nuclear Cardiology, 26, 2065-2123. [Google Scholar] [CrossRef] [PubMed]
[33] Koyama, J., Ray-Sequin, P.A. and Falk, R.H. (2003) Longitudinal Myocardial Function Assessed by Tissue Velocity, Strain, and Strain Rate Tissue Doppler Echocardiography in Patients with AL (Primary) Cardiac Amyloidosis. Circulation, 107, 2446-2452. [Google Scholar] [CrossRef] [PubMed]
[34] Phelan, D., Collier, P., Thavendiranathan, P., Popović, Z.B., Hanna, M., Plana, J.C., et al. (2012) Relative Apical Sparing of Longitudinal Strain Using Two-Dimensional Speckle-Tracking Echocardiography Is Both Sensitive and Specific for the Diagnosis of Cardiac Amyloidosis. Heart, 98, 1442-1448. [Google Scholar] [CrossRef] [PubMed]
[35] Barros-Gomes, S., Williams, B., Nhola, L.F., Grogan, M., Maalouf, J.F., Dispenzieri, A., et al. (2017) Prognosis of Light Chain Amyloidosis with Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. JACC: Cardiovascular Imaging, 10, 398-407. [Google Scholar] [CrossRef] [PubMed]
[36] Nicol, M., Baudet, M., Brun, S., Harel, S., Royer, B., Vignon, M., et al. (2019) Diagnostic Score of Cardiac Involvement in AL Amyloidosis. European Heart Journal-Cardiovascular Imaging, 21, 542-548. [Google Scholar] [CrossRef] [PubMed]
[37] Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., et al. (2019) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 25, 854-865. [Google Scholar] [CrossRef] [PubMed]
[38] Martinez-Naharro, A., Baksi, A.J., Hawkins, P.N. and Fontana, M. (2020) Diagnostic Imaging of Cardiac Amyloidosis. Nature Reviews Cardiology, 17, 413-426. [Google Scholar] [CrossRef] [PubMed]
[39] Karamitsos, T.D., Piechnik, S.K., Banypersad, S.M., Fontana, M., Ntusi, N.B., Ferreira, V.M., et al. (2013) Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 6, 488-497. [Google Scholar] [CrossRef] [PubMed]
[40] Fine, N.M., Davis, M.K., Anderson, K., Delgado, D.H., Giraldeau, G., Kitchlu, A., et al. (2020) Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients with Cardiac Amyloidosis. Canadian Journal of Cardiology, 36, 322-334. [Google Scholar] [CrossRef] [PubMed]
[41] Fine, N.M., Arruda-Olson, A.M., Dispenzieri, A., Zeldenrust, S.R., Gertz, M.A., Kyle, R.A., et al. (2014) Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis. The American Journal of Cardiology, 113, 1723-1727. [Google Scholar] [CrossRef] [PubMed]
[42] Vrana, J.A., Gamez, J.D., Madden, B.J., Theis, J.D., Bergen, H.R. and Dogan, A. (2009) Classification of Amyloidosis by Laser Microdissection and Mass Spectrometry-Based Proteomic Analysis in Clinical Biopsy Specimens. Blood, 114, 4957-4959. [Google Scholar] [CrossRef] [PubMed]
[43] Locke, M. and Nieto, M. (2025) AL Amyloidosis: Current Treatment and Outcomes. Advances in Hematology, 2025, Article ID: 7280805. [Google Scholar] [CrossRef] [PubMed]
[44] Bellofiore, C., Basset, M., Sanna, G.D., Foli, A., Mussinelli, R., Nanci, M., et al. (2025) Daratumumab‐Based Regimens versus Cybord in Newly Diagnosed Patients with AL Amyloidosis and IIIB Cardiac Stage: A Matched Case‐Control Study. HemaSphere, 9, e70112. [Google Scholar] [CrossRef] [PubMed]
[45] D’Souza, A., Dispenzieri, A., Wirk, B., Zhang, M., Huang, J., Gertz, M.A., et al. (2015) Improved Outcomes after Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 33, 3741-3749. [Google Scholar] [CrossRef] [PubMed]
[46] Hartnett, J., Jaber, W., Maurer, M., Sperry, B., Hanna, M., Collier, P., et al. (2021) Electrophysiological Manifestations of Cardiac Amyloidosis. JACC: CardioOncology, 3, 506-515. [Google Scholar] [CrossRef] [PubMed]
[47] Al-Khatib, S.M., Stevenson, W.G., Ackerman, M.J., Bryant, W.J., Callans, D.J., Curtis, A.B., et al. (2018) 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation, 138, e272-e391. [Google Scholar] [CrossRef] [PubMed]
[48] Wei, H., Wang, J., Liang, Y., Xia, S., Li, L. and Zhong, L. (2025) Prophylactic Implantation of Cardioverter‐Defibrillator in Patients with Advanced Light‐Chain Amyloidosis—A Pilot Study. Journal of Arrhythmia, 41, e70068. [Google Scholar] [CrossRef] [PubMed]